Author/year | N | Physical status | TNM stage | Intervention | Duration (cycle) | Outcomes | Methods score | ||
---|---|---|---|---|---|---|---|---|---|
T | C | T | C | ||||||
Ye L et al., 2017 [25] | 30 | 30 | NR | IIIb-IV | TP + XAPI (60 ml/d, d1–10) | TP | 1 | ①②③④⑤⑥⑦ | 8 |
Hu XL et al., 2017 [26] | 53 | 53 | NR | IIIb-IV | GP + XAPI (20 ml/d, d1–15) | GP | 4 | ①③④⑤⑦⑧⑨⑩ | 9 |
Gu N et al., 2016 [27] | 39 | 39 | NR | III-IV | GP + XAPI (22 ml/d, d1–22) | GP | 1 | ①② | 7 |
Liu JR et al., 2016 [28] | 30 | 30 | ZPS ≤ 3 | IIIb-IV | GP + XAPI (40 ml/d, d1–14) | GP | 2 | ①| 7 |
Li XG et al., 2016 [29] | 64 | 58 | KPS > 70 | IIIb-IV | GP + XAPI (80 ml/d, d1–8) | GP | 4 | ①③④⑤ | 7 |
Li QL et al., 2016 [30] | 36 | 36 | KPS > 70 | IIIb-IV | GP + XAPI (40–60 ml/d, d1–15) | GP | 2 | ①②③④⑤⑥⑦⑧ | 9 |
Yao J, 2016 [31] | 53 | 53 | KPS ≥ 61 | IIIb-IV | TP + XAPI (20 ml/d, d1–21) | TP | 2 | ①③④⑤⑪ | 7 |
Song Y et al., 2016 [32] | 40 | 40 | NR | IIIb-IV | GP/NP + XAPI (40 ml/d, d1–15) | GP/NP | 1 | ①③④⑤⑥⑨⑩ | 8 |
Li YL et al., 2015 [33] | 33 | 32 | KPS ≥ 60 | IIIb-IV | TP + XAPI (60 ml/d, d1–15) | TP | 2 | ①②③④⑤⑥⑨⑩⑪ | 8 |
Mei CR et al., 2015 [34] | 30 | 33 | KPS ≥ 60 | IIIb-IV | TP + XAPI (20 ml/d, d1–14) | TP | 2 | ①②③④⑤⑥⑦⑧ | 8 |
Shen LW et al., 2015 [35] | 28 | 28 | KPS ≥ 60 | III-IV | TP + XAPI (40–60 ml/d, d1–15) | TP | 2 | ①③④⑤⑪ | 8 |
Ai L et al., 2015 [36] | 33 | 32 | KPS ≥ 60 | IIIb-IV | TP + XAPI (60 ml/d, d1–14) | TP | 2 | ①②⑨ | 7 |
Shi L et al., 2015 [37] | 26 | 26 | NR | IIIb-IV | TP + XAPI (60 ml/d, d1–14) | TP | 3 | ①| 7 |
Xia GA, 2013 [38] | 39 | 39 | KPS ≥ 50 | IIIb-IV | TP + XAPI (40 ml/d, d1–14) | TP | 2 | ①② | 7 |
Fang H et al., 2013 [39] | 43 | 43 | KPS > 70 | IIIb-IV | GP + XAPI (4 ml/d, d1–8) | GP | 3 | ①③④⑤⑥ | 9 |
Yang WQ et al., 2013 [40] | 37 | 37 | PS 0–2 | IIIb-IV | DP + XAPI (60 ml/d, d1–28) | DP | 2 | ①②③④⑤⑥⑦⑧ | 9 |
Zhang FY et al., 2011 [41] | 24 | 24 | KPS > 50 | IIIb-IV | GP + XAPI (40–60 ml/d, d1–15) | GP | 2 | ①②③④⑤⑫ | 8 |
Yang H et al., 2011 [42] | 30 | 30 | KPS ≥ 60 | IIIb-IV | NP + XAPI (60 ml/d, d1–7) | NP | 2 | ①② | 7 |
Bai RL, 2010 [43] | 36 | 36 | KPS ≥ 60 | IIIa-IV | NP + XAPI (60 ml/d, d1–15) | NP | 1 | ①②⑫ | 7 |
Li J et al., 2009 [44] | 38 | 38 | KPS > 70 | IIIb-IV | GP + XAPI (40 ml/d, d1–15) | GP | 2 | ①②③④⑤⑥⑦⑧⑨ | 8 |
Wang K et al., 2009 [45] | 28 | 28 | KPS > 50 | IIIb-IV | NP + XAPI (20–60 ml/d, d1–15) | NP | 2 | ①②③④⑤⑫ | 8 |
Wang WY et al., 2009 [46] | 27 | 29 | KPS ≥ 70 | IIIb-IV | TP + XAPI (80 ml/d, d1–7) | TP | 2 | ①②⑫ | 7 |
Song CP, 2008 [47] | 36 | 36 | KPS ≥ 60 | IIIa-IV | NP + XAPI (60 ml/d, d1–15) | NP | 2 | ①② | 7 |
Huang ZQ et al., 2007 [48] | 30 | 32 | KPS ≥ 50 | IIIb-IV | GP/TC/NP + XAPI (60 ml/d, d1–15) | GP/TP/NP | 2 | ①②③④⑤⑥⑦⑧⑩⑫ | 8 |